• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    11/20/23 2:35:58 PM ET
    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Real Estate
    Finance
    Medical/Dental Instruments
    Health Care
    Get the next $AIRE alert in real time by email

    Shares of ReNew Energy Global Plc (NASDAQ:RNW) gained during Monday’s session following strong quarterly sales.

    ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million.

    ReNew Energy raised its FY24 adjusted EBITDA guidance to INR 62 billion - INR 66 billion.

    ReNew Energy Global gained 13.6% to $6.74 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Bruush Oral Care Inc. (NASDAQ:BRSH) shares jumped 147.2% to $0.4179. Brüush received Nasdaq notification regarding minimum bid requirements.
    • Cuentas Inc. (NASDAQ:CUEN) shares gained 59% to $1.5098 after reporting a narrower quarterly loss.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) jumped 52% to $0.4280. Altamira Therapeutics recently entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) gained 41.4% to $1.4000. Cardio Diagnostics Holdings announced the publication of its study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association.
    • YPF Sociedad Anónima (NYSE:YPF) shares climbed 40.8% to $15.11. Javier Milei‘s victory in Argentina’s presidential election sparked a rally in Argentine ADRs trading on major U.S. stock exchanges.
    • GD Culture Group Limited (NASDAQ:GDC) rose 26.8% to $4.3074. GD Culture Group unveiled its transformative and photorealistic AI-driven digital human technology on TikTok.
    • Blue Star Foods Corp. (NASDAQ:BSFC) shares gained 26.8% to $0.1752 after jumping 18% on Friday. Blue Star Foods recently signed a 2-year bid award purchase agreement with Sysco Corporation.
    • MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) gained 25.3% to $4.2729. MIRA Pharmaceuticals announced exclusive licensing agreement for oral ketamine analog, Ketamir-2.
    • Grupo Financiero Galicia S.A. (NASDAQ:GGAL) rose 25% to $15.63 after gaining 5% on Friday.
    • Transportadora de Gas del Sur S.A. (NYSE:TGS) shares climbed 23.1% to $12.88 after gaining over 4% on Friday.
    • Central Puerto S.A. (NYSE:CEPU) climbed 23.1% to $7.58.
    • Pampa Energía S.A. (NYSE:PAM) gained 23% to $45.60.
    • Transportadora de Gas del Sur S.A. (NYSE:TGS) rose 22.6% to $12.82 after gaining over 4% on Friday.
    • Banco BBVA Argentina S.A. (NYSE:BBAR) gained 22.4% to $5.40.
    • LogicMark, Inc. (NASDAQ:LGMK) shares rose 22.2% to $2.04. LogicMark recently posted GAAP loss of $1.10 per share for the third quarter.
    • IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) gained 20.3% to $7.79.
    • Telecom Argentina S.A. (NYSE:TEO) climbed 19.4% to $6.40 after gaining around 4% on Friday.
    • Banco Macro S.A. (NYSE:BMA) gained 17.1% to $23.71.
    • HireRight Holdings Corporation (NYSE:HRT) jumped 17.4% to $11.81 after gaining 5% on Friday.
    • Yoshiharu Global Co. (NASDAQ:YOSH) shares climbed 15.7% to $0.4050. The company recently reported an increase in quarterly sales.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 15.6% to $17.00.
    • MediciNova, Inc. (NASDAQ:MNOV) rose 15.2% to $2.0508. The company announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma presented at the 28th Annual Meeting of the Society for Neuro-Oncology.
    • Kronos Bio, Inc.(NASDAQ:KRON) gained 14.4% to $1.2699. Kronos recently posted downbeat quarterly results.
    • Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA) gained 14.4% to $6.80.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) rose 13.6% to $5.74. Goldman Sachs initiated coverage on Iovance Biotherapeutics with a Buy rating and announced a price target of $12.
    • Anavex Life Sciences Corp. (NASDAQ:AVXL) jumped 11.8% to $7.01. The clinical-stage biopharmaceutical company announced that it initiated a regulatory submission with the European Medicines Agency (EMA).
    • Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 11.7% to $31.42. Intellia Therapeutics recently announced it received European Union orphan drug designation for NTLA-2002.
    • XPeng Inc. (NYSE:XPEV) gained 9% to $18.30.
    • Motus GI Holdings, Inc. (NASDAQ:MOTS) gained 7.6% to $3.98 after declining around 5% on Friday. Motus GI recently announced the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.
    • NIO Inc. (NYSE:NIO) fell 6.2% to $7.85. Nio announced on Sunday that it has activated its 2,100th power swap station.
    • Coinbase Global, Inc. (NASDAQ:COIN) gained 4.2% to $103.12.

    Losers

    • NanoString Technologies, Inc. (NASDAQ:NSTG) shares fell 46% to $0.69. TD Cowen downgraded NanoString Technologies from Outperform to Market Perform and lowered the price target from $6 to $1.4.
    • PaxMedica, Inc. (NASDAQ:PXMD) fell 40.6% to $1.04 after the company announced pricing of $7 million public offering of 5,384,615 shares and accompanying warrants at a price of $1.30 per unit.
    • Safe and Green Development Corporation (NASDAQ:SGD) fell 25.5% to $3.14. Safe And Green Development shares jumped 39% on Friday after the company said it does not intend to conduct the offering of the shares of common stock contemplated by the Registration Statement.
    • Alzamend Neuro, Inc. (NASDAQ:ALZN) dipped 25% to $1.2400. Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for major depressive disorder (MDD).
    • Yatsen Holding Limited (NYSE:YSG) fell 24.2% to $0.6559. Yatsen Holding is expected to release its unaudited financial results for the third quarter on Nov. 21, 2023.
    • 2seventy bio, Inc. (NASDAQ:TSVT) declined 16.4% to $1.78. The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal Phase 3 KarMMa-3 study.
    • Allurion Technologies Inc. (NYSE:ALUR) fell 12.6% to $3.72.
    • Safe & Green Holdings Corp. (NASDAQ:SGBX) shares fell 12.6% to $0.6821 after gaining around 7% on Friday. Safe & Green Holdings recently posted a narrower-than-expected quarterly loss.
    • Greenland Technologies Holding Corporation (NASDAQ:GTEC) declined 12.5% to $2.87 following weak quarterly results.
    • reAlpha Tech Corp. (NASDAQ:AIRE) declined 10.5% to $8.40. ReAlpha Tech filed a prospectus for the offering of up to 1.67 million common units at a price of $12 per unit.
    • Applied UV, Inc. (NASDAQ:AUVI) shares fell 9.4% to $0.1340 after the company reported third-quarter results.
    • MGO Global, Inc. (NASDAQ:MGOL) shares fell 9.1% to $0.50 after jumping over 10% on Friday. MGO Global recently posted a wider third-quarter loss.
    • Genelux Corporation (NASDAQ:GNLX) declined 8.7% to $10.83.
    • Tharimmune, Inc. (NASDAQ:THAR) shares fell 8.6% to $0.1922. Tharimmune shares climbed around 17% on Friday after the company announced a 1-for-25 reverse stock split.
    • Chegg, Inc. (NYSE:CHGG) fell 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price target from $10 to $9.

    Now Read This: This Analyst With 84% Accuracy Rate Sees Around 22% Upside In NVIDIA - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

    Get the next $AIRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRE
    $ALUR
    $ALZN
    $AUVI

    CompanyDatePrice TargetRatingAnalyst
    Medicinova Inc
    $MNOV
    3/16/2026$10.00Buy
    H.C. Wainwright
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    Pampa Energia S.A.
    $PAM
    3/12/2026$97.00Hold → Buy
    HSBC Securities
    NIO Inc.
    $NIO
    3/11/2026$6.60Neutral → Buy
    Nomura
    Intellia Therapeutics Inc.
    $NTLA
    3/2/2026Mkt Perform → Outperform
    William Blair
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    IRSA Inversiones Y Representaciones S.A.
    $IRS
    1/30/2026$23.00Outperform
    Itau BBA
    More analyst ratings

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CEO, EXEC CHAIRMAN Rosensweig Daniel bought $56,360 worth of shares (100,000 units at $0.56), increasing direct ownership by 1% to 7,625,075 units (SEC Form 4)

    4 - CHEGG, INC (0001364954) (Issuer)

    2/18/26 6:30:27 AM ET
    $CHGG
    Other Consumer Services
    Real Estate

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MediciNova with a new price target

    H.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00

    3/16/26 8:42:01 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIO upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded NIO from Hold to Buy and set a new price target of $6.80

    3/13/26 8:42:10 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Pampa Energia S.A. upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Pampa Energia S.A. from Hold to Buy and set a new price target of $97.00

    3/12/26 8:40:45 AM ET
    $PAM
    Electric Utilities: Central
    Utilities

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

    New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson's model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced

    3/17/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (NASDAQ:GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for Hydronidone (F351) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). This decision by CDE was made following the pre-NDA communication meeting previously announced on Januar

    3/17/26 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenland Technologies Holding Corporation Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    EAST WINDSOR, N.J., March 16, 2026 /PRNewswire/ -- Greenland Technologies Holding Corporation (NASDAQ:GTEC) ("Greenland" or the "Company"), a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on March 12, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

    3/16/26 4:05:00 PM ET
    $GTEC
    Industrial Machinery/Components
    Industrials

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    SEC Filings

    View All

    SEC Form EFFECT filed by GD Culture Group Limited

    EFFECT - GD Culture Group Ltd (0001641398) (Filer)

    3/19/26 12:15:29 AM ET
    $GDC
    Steel/Iron Ore
    Industrials

    SEC Form DEF 14A filed by GD Culture Group Limited

    DEF 14A - GD Culture Group Ltd (0001641398) (Filer)

    3/18/26 5:17:23 PM ET
    $GDC
    Steel/Iron Ore
    Industrials

    SEC Form 6-K filed by Banco Macro S.A. ADR (representing Ten

    6-K - Macro Bank Inc. (0001347426) (Filer)

    3/18/26 4:32:41 PM ET
    $BMA
    Commercial Banks
    Finance

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Covaro Gonazalo Javier Fernandez

    3 - GRUPO FINANCIERO GALICIA SA (0001114700) (Issuer)

    3/19/26 6:02:35 AM ET
    $GGAL
    Commercial Banks
    Finance

    SEC Form 3 filed by new insider Sinha Sumant

    3 - ReNew Energy Global plc (0001848763) (Issuer)

    3/18/26 9:53:38 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    SEC Form 3 filed by new insider Braun Tomas

    3 - GRUPO FINANCIERO GALICIA SA (0001114700) (Issuer)

    3/18/26 9:33:05 PM ET
    $GGAL
    Commercial Banks
    Finance

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Financials

    Live finance-specific insights

    View All

    reAlpha (NASDAQ: AIRE) Reports Fourth Quarter and Full Year 2025 Results; Record Full-Year Revenue of $4.5 Million, Up 376% Year Over Year

    DUBLIN, Ohio, March 12, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced financial results for the quarter and full year ended December 31, 2025. Full Year Financial Highlights (All figures are approximate and compared to FY 2024 unless otherwise stated) Revenue increased 376% to $4.5 million, compared to $0.9 million in FY 2024. The increase was driven primarily by increased revenue from mortgage brokerage transactions from reAlpha Mortgage, subscription fees from AiChat's AI conversational technologies, and revenues generated from Prevu's real estate services following its acquisition

    3/12/26 8:35:00 AM ET
    $AIRE
    Real Estate
    Finance

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026 Alignment with China's Center for Drug Evaluation (CDE) on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application (NDA) submission for conditional approval expected in the first half of 2026 Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis (PD) trial(272 patients acros

    3/12/26 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter

    3/10/26 6:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Leadership Updates

    Live Leadership Updates

    View All

    reAlpha Tech Corp. Appoints Thomas Kutzman as Chief Financial Officer to Support Growth Strategy

    DUBLIN, Ohio, Feb. 27, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced the appointment of Thomas Kutzman as Chief Financial Officer, effective February 25, 2026. Mr. Kutzman succeeds Piyush Phadke and will oversee the Company's financial operations, capital strategy, and key corporate functions such as human resources and legal, reporting directly to Chief Executive Officer Mike Logozzo. Kutzman brings more than 12 years of financial markets experience to the role. Prior to co-founding Prevu, he held investment and trading roles at SAC Capital, JPMorgan, Citi, and Jabre Capital Partners,

    2/27/26 8:30:00 AM ET
    $AIRE
    Real Estate
    Finance

    Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. "We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "Dr. Paeger brings three decades of strong leade

    2/23/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chegg Appoints Karine Allouche as General Manager, Language Learning, Worldwide and Skills Integration, Europe

    Chegg, Inc. (NYSE:CHGG), a global learning company, today announced that Karine Allouche will join Busuu, Chegg's language learning business, as General Manager of Language Learning, Worldwide, and Skills Integration, Europe, effective February 9, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209423954/en/Karine Allouche In her role, Karine will focus on strengthening execution, accelerating growth, and deepening collaboration across the company, in partnership with Chegg's leadership team and the board. In addition to leading language learning, Karine will own Chegg's European commercial engine and play a key role in

    2/9/26 9:05:00 AM ET
    $CHGG
    Other Consumer Services
    Real Estate

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:57:27 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:53:40 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:32:48 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    $AIRE
    $ALUR
    $ALZN
    $AUVI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care